Lumanity



## Lumanity at ISPOR Europe 2026

From navigating Joint Clinical Assessments to incorporating patient perspectives, our experts are shaping conversations that drive better healthcare decisions at ISPOR Europe 2026 in Vienna.

**Vienna**
**November 8-11**
**Booth #611**

## Exhibit Hall Theater

**Monday, November 9, 2026**
**15:15-15.45 (CET)**

Preparing Orphan Medicinal Products for JCA: Strengthening the Evidence Package

Moderator: ***Suzette Matthijsse***

Speakers: *Miranda Cooper, Triona Zelesnik.*

## Issue Panels

**Monday, November 9, 2026**
**10:30-11:30 (CET)**

Navigating Europe's New Era of Health Policy Reform: How Will the EU HTA Regulation, Pharmaceutical Legislation Revision, Critical Medicines Act, and Biotech Act Shape Medicines Development and Patient Access?

Moderator: ***Suzette Matthijsse***

Speakers: *Rui Santos Ivo, Anne Willemsen, Neil Grubert, Maya Matthews.*

**Monday, November 9, 2026**
**13:45-14:45 (CET)**

First Wave, First Lessons: Multi-Stakeholder Insights from the initial Joint Clinical Assessments Under the European Regulation on Health Technology Assessment

Moderator: ***Suzette Matthijsse***

Speakers: *Anne Willemsen, James Ryan, Niklas Hedberg.*

# Posters

## Poster Session 1
**Monday, November 9**
**10:30 – 13:30 (CET)**

Burden of Illness of Metachromatic Leukodystrophy - An AI Assisted Targeted Literature Review

***Rishabh Verma***, ***Amit Ahuja***.

---

Patient Characteristics, Treatment Patterns and Healthcare Resource Utilization in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients in the Netherlands

***Naomi Reimes***, ***Pauline Kiss***, *Johan Bernardus de Raad*, ***Jelena Pavlovic***, *Margreet Plantenga, Istvan Majer, Moushmi Singh.*

---

## Poster Session 2
**Monday, November 9**
**16:00 – 19:00 (CET)**

Beyond ICD Codes: Using Pathology Data to Identify Biomarker-Defined Cohorts and Clinically Meaningful Subgroups in Real-World Data

***Jelena Pavlović***, ***Ivana Prokić***, ***Nikita Jeswani***, *Qurinus Voorham.*

---

RWD Lessons Learned from Linkages of the PHARMO Data Network and its Applications

***Ilona Verburg***, ***Louise Lemmens***, ***Jetty Overbeek***, ***Nikita Jeswani***.

---

Use and Acceptability of Structured Expert Elicitation in NICE Appraisals

***Ewa Rupniewska***, ***Sameen Mehboob***, ***Chantelle Browne***, ***Colin Burke***.

---

## Poster Session 3
**Tuesday, November 10**
**10:30 – 13:30 (CET)**

Associations Between Bronchiectasis Symptoms and Clinical Outcomes: Protocol for a Systematic Literature Review and Meta-Analysis Feasibility Assessment

*Robin Jha, Kathrin Fischer,* ***Paranjoy Saharia***, ***Vijay Sharma***, ***Conor Hickey***, *Akshay Kharat, Ashok Jha.*

---

Clinical and Humanistic Impact of Using Pembrolizumab Across the Reimbursed Indications in Italy

***Sam Greenall***, *Virginia Eterno,* ***Amy Barber***, ***Catarina Neves***, *Joao Pedro Ferreira, Bernardo Rodrigues, Vivek Khurana, Annabelle Davies.*

---

***Top 5% Finalist for the ISPOR Europe 2026 Research Presentation Award***

Economic Perspectives on Nieman-Pick Disease: A Targeted Review of Econonomic Evidence

***Vijay Sharma***, ***Taruni Donkana***, ***Prakhar Lambhate***, ***Nidhun Praveen***.

---

Projected Health Outcomes and Resource Use: Impact of Introducing Pembrolizumab (Including Intravenous and Subcutaneous Administration) in Early-Stage Head and Neck Squamous Cell Carcinoma (HNSCC) in the U.S. Medicare Population

*Feng (Johnson) Qian,* ***Sam Greenall***, ***Colin Burke***, ***Catarina Neves***, *Yizhen Lai.*

---

The Clinical and Humanistic Impact of Pembrolizumab in the Czech Republic: A Population-level Pan-Tumor Modeling Study

*Tomas Mlcoch, Leona Popelkova,* ***Autumn Hoang***, ***Amy Barber***, ***Catarina Neves***, *Joao Pedro Ferreira, Bernardo Rodrigues, Annabelle Davies, Vivek Khurana.*

---

## Poster Session 4
**Tuesday, November 10**
**16:00 – 19:00 (CET)**

***Top 5% Finalist for the ISPOR Europe 2026 Research Presentation Award***

Economic Impact of Early Diagnosis and Immunoglobulin Treatment for Inborn Errors of Immunity with Focus on Common Variable Immunodeficiency (CVID) in Brazil: A Cost-Effectiveness Perspective

Batyrkhan Kuatov, **Annaëlle Vinzent**, **Autumn Hoang**, Melike Inkaya Taskin, **Chrissy Lowry**, Lilian Pititto, Ekaterini Simões Goudouris.

---

Frequency and Acceptability of Severity Modifier in NICE Technology Appraisals

***Ewa Rupniewska***, ***Ayesha Qureshi***, ***Benjamin Farrar***, ***Benjamin Christopher Kearns***.

---

The Difference Matters (Even When It's Null): A Practical Framework for Sex- and Age-stratified RWE

***Brenda Baak***, ***Ivana Prokic***, ***Anna Newton***, ***Naomi Boxall***.

---

## Poster Session 5
**Wednesday, November 11**
**09:00 – 11:30 (CET)**

Are We READI for Disease-Specific Reference Case Extensions? Lessons from NICE's Obesity Framework

***Izzy Thornton***, ***Cameron Lilley***.

---

Economic Burden of Progressive Supranuclear Palsy: A Targeted Literature Review

***Taruni Donkana***, ***Vijay Sharma***, ***Prakhar Lambhate***, ***Debjit Ghoshal***.

---

The Association Between Event-Free Survival (EFS) and Overall Survival (OS) in High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) in the Netherlands: An Observational Study of Electronic Health Record

*Leo Chen, Joseph C. Cappelleri, Jane Chang, Julia Brinkmann, Hollie Pilkington,* ***Sarah Smith***, ***Louise Lemmens***, ***Sarah Bailey***, ***Jetty Overbeek***, ***Patricia Silva***, ***Meena Venkatachalam***, *Anthony Eccleston.*

---

Tipping Point Quantitative Bias Analysis Approaches to Population-adjusted Indirect Comparisons with Incomplete Data

***Emma Mackay***, ***Devon Boyne***.

---